APA (7th ed.) Citation

AL, F., SK, Y., K, L., L, G., J, B., L, G., . . . M, G. (2022). Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. MMWR. Morbidity and mortality weekly report, 71(11), 422. https://doi.org/10.15585/mmwr.mm7111e1

Chicago Style (17th ed.) Citation

AL, Fowlkes, et al. "Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) MRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022." MMWR. Morbidity and Mortality Weekly Report 71, no. 11 (2022): 422. https://doi.org/10.15585/mmwr.mm7111e1.

MLA (9th ed.) Citation

AL, Fowlkes, et al. "Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) MRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022." MMWR. Morbidity and Mortality Weekly Report, vol. 71, no. 11, 2022, p. 422, https://doi.org/10.15585/mmwr.mm7111e1.